Literature DB >> 22228418

Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning.

Hong Xu1, Ziqiang Zhu, Yiming Huang, Larry D Bozulic, Lala-Rukh Hussain, Jun Yan, Suzanne T Ildstad.   

Abstract

BACKGROUND: Mixed chimerism is an effective approach for tolerance induction in transplantation. Strategies to achieve mixed chimerism with relatively low toxicity have significantly expanded the clinical use of chimerism.
METHODS: Allogeneic bone marrow transplants were performed between B6 (H2(b)) and BALB/c (H2(d)) mice. Recipient B6 mice were nonmyeloablatively conditioned with anti-αβ-T-cell receptor, anti-CD154, or rapamycin alone or in different combinations. A total of 15 × 10(6) BALB/c bone marrow cells were transplanted after varying doses of cGy of total body irradiation.
RESULTS: Pretreatment of recipients with anti-CD154 and rapamycin with or without T-cell lymphodepletion reduced the total body irradiation requirement to 100 cGy for establishing stable mixed chimerism. The mixed chimeras accepted donor islet allografts long term. Lymphocytes from mixed chimeras did not respond to host or donor antigens, yet were reactive to major histocompatibility complex-disparate third-party alloantigens, demonstrating functional donor-specific T-cell tolerance. No antibodies against donor and host were detected in mixed chimeras, suggesting humoral tolerance. Mixed chimeras showed no cytotoxicity to donor cells, but a similar rapid killing rate for major histocompatibility complex disparate third-party B10.BR cells compared with T-cell-deficient and wild-type controls in in vivo cytotoxicity assays, suggesting donor-specific tolerance in the innate immune cells was achieved in mixed chimeras.
CONCLUSIONS: Mixed chimeras prepared with low-intensity nonmyeloablative conditioning exhibit systemic tolerance in innate immunity and tolerance in adaptive T- and B-cell immune responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228418      PMCID: PMC3613854          DOI: 10.1097/TP.0b013e318242bddf

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  47 in total

Review 1.  T and B cell cooperation: a dance of life and death.

Authors:  Alain Bernard; Sylvie Coitot; Aurore Brémont; Ghislaine Bernard
Journal:  Transplantation       Date:  2005-02-15       Impact factor: 4.939

2.  Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.

Authors:  Y L Colson; H Li; S S Boggs; K D Patrene; P C Johnson; S T Ildstad
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

Review 3.  Long-lived plasma cells: a mechanism for maintaining persistent antibody production.

Authors:  M K Slifka; R Ahmed
Journal:  Curr Opin Immunol       Date:  1998-06       Impact factor: 7.486

4.  Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance.

Authors:  A Khan; Y Tomita; M Sykes
Journal:  Transplantation       Date:  1996-08-15       Impact factor: 4.939

5.  Tolerance of Sk-incompatible skin grafts.

Authors:  E A Boyse; E A Carswell; M P Scheid; L J Old
Journal:  Nature       Date:  1973-08-17       Impact factor: 49.962

6.  Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning.

Authors:  M Sykes; G L Szot; K A Swenson; D A Pearson
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

7.  Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection.

Authors:  H Ohdan; Y G Yang; A Shimizu; K G Swenson; M Sykes
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

8.  A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.

Authors:  Y L Colson; S M Wren; M J Schuchert; K D Patrene; P C Johnson; S S Boggs; S T Ildstad
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

9.  A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases.

Authors:  S B Vercauteren; J L Bosmans; M M Elseviers; G A Verpooten; M E De Broe
Journal:  Kidney Int       Date:  1998-08       Impact factor: 10.612

10.  Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins.

Authors:  O Farges; F Saliba; H Farhamant; D Samuel; A Bismuth; M Reynes; H Bismuth
Journal:  Hepatology       Date:  1996-02       Impact factor: 17.425

View more
  5 in total

Review 1.  The hematopoietic system in the context of regenerative medicine.

Authors:  Christopher D Porada; Anthony J Atala; Graça Almeida-Porada
Journal:  Methods       Date:  2015-08-28       Impact factor: 3.608

2.  Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model.

Authors:  C D Fitzhugh; R P Weitzel; M M Hsieh; O A Phang; C Madison; L Luznik; J D Powell; J F Tisdale
Journal:  Bone Marrow Transplant       Date:  2013-04-22       Impact factor: 5.483

Review 3.  Stem cell therapy to cure type 1 diabetes: from hype to hope.

Authors:  Preeti Chhabra; Kenneth L Brayman
Journal:  Stem Cells Transl Med       Date:  2013-04-09       Impact factor: 6.940

4.  Application of allogeneic bone marrow cells in view of residual alloreactivity: sirolimus but not cyclosporine evolves tolerogenic properties.

Authors:  Kai Timrott; Florian W R Vondran; Hueseyin Bektas; Jürgen Klempnauer; Mark D Jäger
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

Review 5.  The need for inducing tolerance in vascularized composite allotransplantation.

Authors:  Kadiyala V Ravindra; Hong Xu; Larry D Bozulic; David D Song; Suzanne T Ildstad
Journal:  Clin Dev Immunol       Date:  2012-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.